BioNTech SE ADR

BNTXNASDAQ · USD
80.96USD0.00 (-0.52%)
545

BioNTech SE ADR (BNTX) Covered Calls

BioNTech SE ADR trades in the Biotechnology industry with an IV Rank of 77.78%, high versus the past year. BNTX's highest covered call setup is the $100.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 23.52% out of the money with 28 days to expiration, a 23.83% return until expiration, and a 310.60% theoretical annualized return. Across the setups shown, annualized returns run from 153.69% to 310.60% at strikes between $90.00 and $175.00, with 28 to 273 days to expiration, as of Nov 20, 2026.

Read more

Running BNTX covered calls helps you generate income from BioNTech SE ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BNTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BNTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BNTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BNTX covered call is worth writing.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

2026-12-1828100.0023.520.250.951929.0023.83310.60-0.31+0.112380.70
2027-01-1556110.0035.870.050.502909.0035.93234.20-0.06+0.059030.45
2026-12-182895.0017.340.250.801429.0017.65230.09-0.31+0.115380.55
2027-01-1556105.0029.690.101.202414.0029.82194.34-0.12+0.101561.10
2026-12-182892.5014.250.201.351174.0014.50189.03-0.25+0.161751.15
2027-05-21182150.0085.280.151.756919.0085.46171.39-0.19+0.08951.60
2026-12-182890.0011.171.051.251009.0012.46162.46-1.30+0.224370.20
2027-05-21182145.0079.100.251.856429.0079.41159.26-0.31+0.096081.60
2027-08-20273175.00116.160.052.659409.00116.22155.38-0.06+0.09182.60
2027-01-1556100.0023.520.052.451909.0023.58153.69-0.06+0.178352.40

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank77.78% High
  • Market cap (M$)20,072
  • 52 weeks high-34.71%
  • 52 weeks low1.81%
  • Analyst recommendationBuy
    1.71
  • Target price$114.94
    41.97% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-03
  • P/E—
  • Future P/E—
  • EPS (ttm)-6.87
  • EPS growth next 5 years4.40%

As of Nov 20, 2026